Brief: Cerenis Therapeutics Reports Results Of The Phase I Study Of Repeated And Increasing Doses To Assess CER-209 In NASH/NAFLD

Abionyx Pharma SA

21/12/2018 07:41

Dec 21(Reuters) - CERENIS THERAPEUTICS HOLDING SA
 CEREN.PA :
    * REPORTED ON THURSDAY RESULTS OF THE PHASE I STUDY OF
REPEATED
AND INCREASING DOSES TO ASSESS CER-209 IN NASH/NAFLD
    * ABSENCE OF ANY MAJOR ADVERSE EVENTS, CONFIRMING CER-209’S
FAVORABLE SAFETY AND TOLERANCE PROFILE
    * DAILY ADMINISTRATION OF INCREASING DOSES OF CER-209 OVER A
28-DAY PERIOD IN PATIENTS WITH A HIGH RISK OF NAFLD/NASH
DEMONSTRATED PROPORTIONAL INCREASE IN CER-209 BLOOD LEVELS
    * MECHANISM OF ACTION VIA THE P2Y13 RECEPTOR SUPPORTED BY
CHANGES
IN HDL CHOLESTEROL

    
 Source text for Eikon:  urn:newsml:reuters.com:*:nBw4GTdjYa
    
 Further company coverage:  CEREN.PA  
   


 (Gdynia Newsroom)
 ((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))